<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Daily Briefing - February 02, 2026</title>
    <style>
        :root {
            --bg: #0d1117;
            --bg-secondary: #161b22;
            --bg-tertiary: #21262d;
            --text: #e6edf3;
            --text-secondary: #8b949e;
            --text-tertiary: #6e7681;
            --accent: #58a6ff;
            --accent-subtle: #388bfd26;
            --border: #30363d;
            --green: #3fb950;
            --green-subtle: rgba(63, 185, 80, 0.15);
            --yellow: #d29922;
            --yellow-subtle: rgba(210, 153, 34, 0.15);
            --red: #f85149;
        }

        @media (prefers-color-scheme: light) {
            :root {
                --bg: #ffffff;
                --bg-secondary: #f6f8fa;
                --bg-tertiary: #eaeef2;
                --text: #1f2328;
                --text-secondary: #656d76;
                --text-tertiary: #8b949e;
                --accent: #0969da;
                --accent-subtle: #0969da1a;
                --border: #d0d7de;
                --green: #1a7f37;
                --green-subtle: rgba(26, 127, 55, 0.12);
                --yellow: #9a6700;
                --yellow-subtle: rgba(154, 103, 0, 0.12);
                --red: #cf222e;
            }
        }

        * {
            box-sizing: border-box;
            margin: 0;
            padding: 0;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Noto Sans', Helvetica, Arial, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.6;
            padding: 0;
            min-height: 100vh;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            padding: 2rem 1.5rem;
        }

        header {
            margin-bottom: 2.5rem;
            padding-bottom: 1.5rem;
            border-bottom: 1px solid var(--border);
        }

        h1 {
            font-size: 1.75rem;
            font-weight: 600;
            margin-bottom: 0.25rem;
            letter-spacing: -0.02em;
        }

        .subtitle {
            color: var(--text-secondary);
            font-size: 0.95rem;
        }

        .stats {
            display: flex;
            gap: 1.5rem;
            margin-top: 0.75rem;
            font-size: 0.85rem;
            color: var(--text-secondary);
        }

        .stat-value {
            color: var(--text);
            font-weight: 600;
        }

        .nav-links {
            display: flex;
            gap: 1rem;
            margin-top: 1rem;
        }

        .nav-links a {
            color: var(--accent);
            text-decoration: none;
            font-size: 0.9rem;
        }

        .nav-links a:hover {
            text-decoration: underline;
        }

        /* Video Cards */
        .video-card {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 1.25rem;
            overflow: hidden;
        }

        .video-header {
            padding: 1.25rem 1.5rem 1rem;
        }

        .video-title {
            font-size: 1.05rem;
            font-weight: 600;
            margin-bottom: 0.6rem;
            line-height: 1.4;
        }

        .video-title a {
            color: var(--text);
            text-decoration: none;
            transition: color 0.15s ease;
        }

        .video-title a:hover {
            color: var(--accent);
        }

        .video-meta {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 0.6rem;
            font-size: 0.8rem;
            color: var(--text-tertiary);
        }

        .channel-info {
            display: inline-flex;
            align-items: center;
            gap: 0.45rem;
        }

        .channel-icon {
            width: 22px;
            height: 22px;
            border-radius: 50%;
            object-fit: cover;
            flex-shrink: 0;
            background: var(--bg-tertiary);
        }

        .channel-name {
            font-weight: 500;
            color: var(--text);
        }

        .channel-subs {
            color: var(--text-tertiary);
            font-size: 0.75rem;
        }

        /* Channel Pill */
        .channel-pill {
            display: inline-flex;
            align-items: center;
            gap: 0.4rem;
            background: var(--bg-tertiary);
            padding: 0.3rem 0.7rem 0.3rem 0.4rem;
            border-radius: 20px;
            font-size: 0.8rem;
        }

        .channel-pill .channel-icon {
            width: 20px;
            height: 20px;
        }

        .channel-pill .channel-name {
            font-weight: 500;
            color: var(--text);
        }

        .channel-pill .channel-subs {
            color: var(--text-tertiary);
            font-size: 0.7rem;
            margin-left: 0.15rem;
        }

        /* Tags */
        .video-tags {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin-top: 0.6rem;
        }

        .tag {
            display: inline-block;
            background: var(--accent-subtle);
            color: var(--accent);
            padding: 0.2rem 0.6rem;
            border-radius: 12px;
            font-size: 0.72rem;
            font-weight: 500;
        }

        .tag-person {
            background: rgba(136, 87, 255, 0.15);
            color: #a371f7;
        }

        .tag-company {
            background: var(--green-subtle);
            color: var(--green);
        }

        .tag-event {
            background: var(--yellow-subtle);
            color: var(--yellow);
        }

        @media (prefers-color-scheme: light) {
            .tag-person {
                background: rgba(130, 80, 223, 0.12);
                color: #6639ba;
            }
        }

        .channel-badge {
            background: var(--accent-subtle);
            color: var(--accent);
            padding: 0.2rem 0.55rem;
            border-radius: 4px;
            font-size: 0.75rem;
            font-weight: 500;
        }

        .high-trust-badge {
            background: var(--green-subtle);
            color: var(--green);
        }

        .meta-sep {
            color: var(--border);
        }

        /* TL;DR Section */
        .tldr {
            padding: 0.9rem 1.5rem;
            background: var(--bg-tertiary);
            border-top: 1px solid var(--border);
            font-size: 0.9rem;
            color: var(--text-secondary);
            line-height: 1.55;
        }

        /* Summary Section */
        .summary-section {
            padding: 1rem 1.5rem 1.25rem;
            border-top: 1px solid var(--border);
        }

        .summary-preview {
            font-size: 0.92rem;
            line-height: 1.7;
            color: var(--text);
        }

        .summary-full {
            display: none;
            font-size: 0.92rem;
            line-height: 1.7;
        }

        .summary-full.expanded {
            display: block;
        }

        .summary-full h3 {
            font-size: 0.95rem;
            font-weight: 600;
            color: var(--text);
            margin: 1.25rem 0 0.6rem;
        }

        .summary-full h3:first-child {
            margin-top: 0;
        }

        .summary-full h4 {
            font-size: 0.9rem;
            font-weight: 600;
            color: var(--text);
            margin: 1rem 0 0.4rem;
        }

        .summary-full ul {
            margin: 0.4rem 0;
            padding-left: 1.3rem;
        }

        .summary-full li {
            margin: 0.35rem 0;
        }

        /* Nested lists - indentation only, no color/size change */
        .summary-full ul ul {
            margin: 0.2rem 0;
        }

        .summary-full ul ul li {
            margin: 0.25rem 0;
        }

        .summary-full strong {
            color: var(--text);
            font-weight: 600;
        }

        .summary-full p {
            margin: 0.6rem 0;
            line-height: 1.65;
        }

        .summary-full blockquote {
            margin: 1rem 0;
            padding: 0.75rem 1rem;
            background: var(--bg-tertiary);
            border-left: 3px solid var(--accent);
            border-radius: 0 6px 6px 0;
            font-style: italic;
            color: var(--text-secondary);
        }

        .summary-full em {
            font-style: italic;
        }

        /* Toggle Buttons */
        .toggle-btn {
            background: none;
            border: none;
            color: var(--accent);
            padding: 0;
            font-size: 0.85rem;
            font-weight: 500;
            cursor: pointer;
            margin-top: 0.6rem;
            display: inline-flex;
            align-items: center;
            gap: 0.3rem;
            transition: opacity 0.15s ease;
        }

        .toggle-btn:hover {
            opacity: 0.8;
        }

        .toggle-btn svg {
            width: 16px;
            height: 16px;
            transition: transform 0.2s ease;
        }

        .toggle-btn.expanded svg {
            transform: rotate(180deg);
        }

        /* Transcript Section */
        .transcript-section {
            padding: 0 1.5rem 1.25rem;
        }

        .transcript-toggle {
            background: var(--bg-tertiary);
            border: 1px solid var(--border);
            color: var(--text-secondary);
            padding: 0.5rem 0.9rem;
            border-radius: 6px;
            font-size: 0.8rem;
            font-weight: 500;
            cursor: pointer;
            transition: all 0.15s ease;
        }

        .transcript-toggle:hover {
            background: var(--border);
            color: var(--text);
        }

        .transcript-content {
            display: none;
            margin-top: 0.75rem;
            padding: 1rem;
            background: var(--bg);
            border-radius: 6px;
            font-size: 0.85rem;
            line-height: 1.75;
            white-space: pre-wrap;
            max-height: 400px;
            overflow-y: auto;
            border: 1px solid var(--border);
            color: var(--text-secondary);
        }

        .transcript-content.expanded {
            display: block;
            animation: fadeIn 0.2s ease;
        }

        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }

        /* Empty State */
        .empty-state {
            text-align: center;
            padding: 4rem 2rem;
            color: var(--text-secondary);
        }

        .empty-state h2 {
            font-size: 1.2rem;
            margin-bottom: 0.4rem;
            color: var(--text);
        }

        /* Index Page Styles */
        .day-list {
            list-style: none;
        }

        .day-card {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 1rem;
            overflow: hidden;
            transition: border-color 0.15s ease;
        }

        .day-card:hover {
            border-color: var(--accent);
        }

        .day-card a {
            display: block;
            padding: 1.25rem 1.5rem;
            text-decoration: none;
            color: inherit;
        }

        .day-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 0.75rem;
        }

        .day-date {
            font-weight: 600;
            font-size: 1rem;
            color: var(--text);
        }

        .day-count {
            color: var(--text-tertiary);
            font-size: 0.85rem;
        }

        .day-previews {
            display: flex;
            flex-direction: column;
            gap: 0.6rem;
        }

        .day-preview-item {
            display: flex;
            flex-direction: column;
            gap: 0.15rem;
            padding: 0.5rem 0;
            border-bottom: 1px solid var(--border);
        }

        .day-preview-item:last-child {
            border-bottom: none;
            padding-bottom: 0;
        }

        .preview-meta {
            display: flex;
            align-items: center;
            gap: 0.4rem;
            font-size: 0.75rem;
            color: var(--text-tertiary);
        }

        .preview-channel-icon {
            width: 16px;
            height: 16px;
            border-radius: 50%;
            object-fit: cover;
            flex-shrink: 0;
        }

        .preview-title {
            font-size: 0.9rem;
            font-weight: 500;
            color: var(--text);
            line-height: 1.3;
        }

        .preview-tldr {
            font-size: 0.8rem;
            color: var(--text-tertiary);
            line-height: 1.4;
        }

        footer {
            margin-top: 3rem;
            padding-top: 1.5rem;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-tertiary);
            font-size: 0.8rem;
        }

        /* Mobile Adjustments */
        @media (max-width: 600px) {
            .container {
                padding: 1.25rem 1rem;
            }

            .video-header, .tldr, .summary-section, .transcript-section {
                padding-left: 1rem;
                padding-right: 1rem;
            }

            .video-title {
                font-size: 1rem;
            }

            .transcript-content {
                max-height: 300px;
            }
        }
        </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Daily Briefing</h1>
            <p class="subtitle">February 02, 2026</p>
            <div class="stats">
                <span><span class="stat-value">1</span> videos</span>
            </div>
            <nav class="nav-links">
                <a href="index.html">&larr; All Briefings</a>
            </nav>
        </header>

        <main>
            
            <article class="video-card">
                <div class="video-header">
                    <h2 class="video-title">
                        <a href="https://www.youtube.com/watch?v=zbiEYMapsvw" target="_blank" rel="noopener">NVIDIA &amp; Eli Lilly: The AI Revolution in Drug Discovery | Jensen Huang &amp; David Ricks</a>
                    </h2>
                    <div class="video-meta">
                        <span class="channel-pill"><img class="channel-icon" src="https://yt3.ggpht.com/btm1_PK-7VRUr9GY2D0UV_2XfbUZPBjghyptjSO1crsfN86HyTYDWPmUbq7JxC3H0Lxe_s067nA=s240-c-k-c0x00ffffff-no-rj" alt="" loading="lazy"><span class="channel-name">NVIDIA</span><span class="channel-subs">(2.1M)</span></span>
                        <span class="meta-sep">·</span><span>58:44</span>
                        
                        <span class="meta-sep">·</span>
                        <span>2026-02-02</span>
                    </div>
                    <div class="video-tags"><span class="tag tag-person">Jensen Huang</span> <span class="tag tag-company">NVIDIA</span> <span class="tag tag-event">Keynote</span></div>
                </div>
                <div class="tldr">&gt; &quot;In the last 10 years, we've accelerated AI about a million times.</div>
                <div class="summary-section">
                    <div class="summary-preview" id="preview-0">TL;DR: NVIDIA and Eli Lilly are partnering to revolutionize drug discovery by building the world's largest dedicated on-prem biology supercomputer and a co-innovation lab, applying advanced AI to simulate human biology and accelerate the development of new medicines.   ...</div>
                    <div class="summary-full" id="full-0">
                        <h3>Executive Briefing: NVIDIA &amp; Eli Lilly: The AI Revolution in Drug Discovery</h3>
<p><strong>TL;DR:</strong> NVIDIA and Eli Lilly are partnering to revolutionize drug discovery by building the world's largest dedicated on-prem biology supercomputer and a co-innovation lab, applying advanced AI to simulate human biology and accelerate the development of new medicines.</p>
<h3>## The NVIDIA AI Advantage &amp; Accelerated Computing</h3>
<ul>
<li><strong>Accelerated Computing Evolution:</strong></li>
<ul>
<ul>
<li>NVIDIA has pioneered accelerated computing for 33 years, achieving <strong>1 millionx AI acceleration in 10 years</strong>, significantly outpacing Moore's Law (100x over 10 years).</li>
<li>This acceleration, achieved by co-designing the entire computing stack, aims to tackle humanity's most impactful challenges.</li>
</ul>
</ul>
<li><strong>Transformative AI Breakthroughs:</strong></li>
<ul>
<ul>
<li><strong>Computer Graphics:</strong> Ray tracing, once a decades-long problem, is now real-time and photorealistic in games, augmented by AI.</li>
<li><strong>Self-Driving Cars:</strong> Approaching a "ChatGPT moment," with robo-taxi capabilities becoming standard in new cars within a decade, driven by multimodality AI and reasoning.</li>
<li><strong>Generative AI &amp; LLMs:</strong> Recent breakthroughs in multimodality AI, reasoning, and agentic capabilities have transformed AI into an "incredibly useful" tool, applicable across diverse industries, including life sciences.</li>
</ul>
</ul>
<li><strong>NVIDIA's Life Sciences Platforms:</strong></li>
<ul>
<ul>
<li><strong>Key Libraries:</strong> NVIDIA offers platforms like <strong>Parabricks</strong> for gene sequencing (achieving a Guinness World Record), <strong>MONAI</strong> (an open-source platform for medical imaging with 6 million downloads), and <strong>BioNeMo</strong> for understanding geometric structures like molecules and proteins.</li>
<li><strong>Dominant Role:</strong> The vast majority of the world's structure prediction models are built on NVIDIA platforms today.</li>
<li><strong>Pre-trained Models:</strong> BioNeMo includes pre-trained models and data for protein design (<strong>Laortina</strong>), molecular synthesis (<strong>Resin</strong>), toxicity prediction (<strong>Kermit</strong>), DNA foundation models (<strong>Evo 2</strong>), and RNA design (<strong>Codon FM</strong>).</li>
<li><strong>Future Vision:</strong> Developing foundation models for proteins, with foundation models for cells "just around the corner."</li>
</ul>
</ul>
</ul>
<h3>## Eli Lilly's Innovation Strategy &amp; GLP-1 Success</h3>
<ul>
<li><strong>Resilience &amp; Accelerated R&amp;D:</strong></li>
<ul>
<ul>
<li>Eli Lilly, a 150-year-old company, has a history of navigating challenging industry cycles and patent cliffs by being "relentless on invention," uniquely surviving without mergers.</li>
<li><strong>Streamlined Processes:</strong> Lilly systematically optimized its R&amp;D, making it approximately <strong>40% faster</strong> than other large pharmaceutical companies, enabling invention within existing patent cycles.</li>
</ul>
</ul>
<li><strong>GLP-1 Market Leadership:</strong></li>
<ul>
<ul>
<li><strong>Pioneering Role:</strong> Lilly launched the world's first GLP-1 treatment in 2006.</li>
<li><strong>Strategic Execution:</strong> Through sustained innovation, including the development of Tirzepatide (a dual GLP-1/GIP medicine like Zepbound), Lilly became the market leader in GLP-1 treatments last year, with a triple-acting variant anticipated in 2027.</li>
</ul>
</ul>
<li><strong>Continuous Innovation:</strong> CEO David Ricks emphasizes the ongoing need to create conditions for new "success cycles" to ensure sustained growth and impact beyond current blockbuster drugs.</li>
</ul>
<h3>## A Transformative Partnership: NVIDIA &amp; Eli Lilly Co-Innovate</h3>
<ul>
<li><strong>Shared Vision for Infrastructure:</strong> Both Jensen Huang and David Ricks highlight the critical importance of building advanced computing infrastructure to attract top scientific talent and foster groundbreaking discoveries in AI and biology.</li>
<li><strong>Key Partnership Pillars:</strong></li>
<ul>
<ul>
<li><strong>Biology Supercomputer:</strong> The world's largest dedicated <strong>on-prem biology supercomputer</strong> is being built in Indianapolis, expected to be operational this week.</li>
<li><strong>Bay Area Co-Innovation Lab:</strong> A joint Lilly-NVIDIA AI lab will be established in the Silicon Valley area, bringing together leading computer scientists and drug discovery experts.</li>
</ul>
</ul>
<li><strong>AI-Driven Discovery Mechanisms:</strong></li>
<ul>
<ul>
<li><strong>Foundation Models:</strong> The lab will focus on developing new foundation models for proteins and cells.</li>
<li><strong>Closed-Loop Scientific Flywheel:</strong> AI will drive protein/chemical synthesis, which will then be validated in robotic wet labs to collect ground truth data. This data will continuously feed back into the models, creating a "scientific flywheel on steroids" to accelerate discovery.</li>
</ul>
</ul>
<li><strong>"Digital Twin" for Biology:</strong></li>
<ul>
<ul>
<li>Jensen Huang envisions applying the "computer-aided design" paradigm, which allows 15,000 engineers to design complex chips that work perfectly on the first try, to human biology.</li>
<li>This aims to transform drug discovery from an "empirical" process (like "wandering around the forest looking for truffles") into a precise engineering problem, performing much of the work "in silico."</li>
</ul>
</ul>
</ul>
<h3>## Beyond Obesity: AI's Role in Future Healthcare Frontiers</h3>
<ul>
<li><strong>Broadening GLP-1 Impact:</strong></li>
<ul>
<ul>
<li><strong>Chronic Disease Lynchpin:</strong> Obesity is a key driver for over 200 chronic diseases; GLP-1s provide a synthetic "off switch" for hunger, addressing modern caloric abundance.</li>
<li><strong>Expanded Benefits:</strong> Zepbound users experience an average 23% body weight loss and a 93% reduction in pre-diabetes conversion. Emerging research shows non-obvious benefits, including reduced chronic inflammation (e.g., improved psoriatic arthritis) and potential in brain health (addiction, gambling, alcohol, smoking cessation).</li>
<li><strong>Future Delivery &amp; Reach:</strong> An oral GLP-1 form is set to launch this spring, significantly enhancing convenience and global scalability, especially for regions with high diabetes prevalence like Southeast Asia.</li>
<li><strong>Historical Parallel:</strong> David Ricks likens the potential impact of GLP-1s to that of antibiotics, which drove a 60-year wave of medical breakthroughs by conquering acute infections.</li>
</ul>
</ul>
<li><strong>Focus on Healthy Longevity:</strong> Eli Lilly's approach to longevity is to extend healthy human lifespan by eradicating disease (e.g., through GLP-1s addressing chronic ailments) rather than solely focusing on extending maximum biological shelf-life.</li>
<li><strong>Next Frontier: Brain Health:</strong> Significant efforts are directed at tackling dementia and other diseases of the aging brain, leveraging AI to simulate brain tissue, understand complex interactions (e.g., inflammation, protein misfolding), and discover new therapeutic targets.</li>
</ul>
<h3>## Accelerating Drug Discovery Through AI &amp; Collaboration</h3>
<ul>
<li><strong>AI Lab Research Directives:</strong></li>
<ul>
<ul>
<li><strong>Drug Engineering/Optimization:</strong> A highly tractable problem for the joint lab, focusing on optimizing new modalities (e.g., RNA, gene therapies) and refining drug designs for known targets.</li>
<li><strong>Target Discovery:</strong> A more challenging endeavor requiring robotic wet labs to run 24/7, generating massive experimental data to fully profile targets and their structural complexities, closing the loop with engineered drug designs.</li>
</ul>
</ul>
<li><strong>Synthetic Data Flywheel:</strong> The ultimate vision involves creating a "synthetic data flywheel" where AI models are trained and tested against sophisticated "world models" (representing the lab itself), reducing the need for constant physical experimentation while remaining grounded by real-world data.</li>
<li><strong>Collaborative Ecosystem:</strong></li>
<ul>
<ul>
<li><strong>Tune Labs:</strong> Lilly's visionary platform, built on NVIDIA's federated learning (NVFlare), enables startups and third parties to collaborate on drug discovery, contributing data and benefiting from improved models without co-mingling sensitive intellectual property.</li>
<li><strong>Broader AI in Healthcare:</strong> AI is rapidly being adopted in healthcare services (e.g., agentic AI, Lilly Direct's $4B/year pharmacy platform) to enhance efficiency and foster innovation, despite existing industry frictions.</li>
</ul>
</ul>
<li><strong>Lilly's Tech Legacy:</strong> David Ricks highlights Lilly's long history of leveraging cutting-edge technology, including developing the first approved biotech product (Humulin with Genentech), acquiring the first pharmaceutical supercomputer (a Cray "Big Red"), and designing the first computer-designed medicine (Humalog). This partnership is a natural evolution of that legacy.</li>
</ul>
<h3>Notable Quotes</h3>
<blockquote>
"In the last 10 years, we've accelerated AI about a million times. A million times versus a hundred times. A million times compounded over 20 years gives us an opportunity to maybe address some of the most incredible, most impactful challenges of humanity."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>Jensen Huang, CEO, NVIDIA</strong>
"We systematically took apart the R&amp;D process literally like every step... and we squished the time. And so still today probably Lily is about 40% faster than the next scaled pharma company on average across all therapeutic areas."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>David Ricks, CEO, Eli Lilly</strong>
"Finally, the computer you know a million times a million times a quadrillion times of computing power later. I think finally we might be able to represent one of the hardest problems in the world which is the human biology. And I'm really hoping that your industry moves from drug discovery, which is kind of like wandering around the forest looking for truffles, to being an engineering problem."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>Jensen Huang, CEO, NVIDIA</strong>
"If we can make that an engineering problem versus this sort of discovery arteasonal drug making problem, think of the impact on human life."
</blockquote>
<p>&gt;</p>
<blockquote>
— <strong>David Ricks, CEO, Eli Lilly</strong>
</blockquote>
                    </div>
                    <button class="toggle-btn" id="sum-btn-0" onclick="toggleSummary(0)">
                        Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>
                    </button>
                </div>
                
                <div class="transcript-section">
                    <button class="transcript-toggle" id="trans-btn-0" onclick="toggleTranscript(0)">
                        View transcript
                    </button>
                    <div class="transcript-content" id="transcript-0">
                        Hello. It's great to see all of you. Once a year I get the benefit of thanking all of you for the incredible work that you do. As you know, we pioneered a new way of doing computing called accelerated computing. And we've been working on this for now 33 years. The big idea is that if you could co-design – meaning if you understood the problems you're trying to compute for, and you developed the entire stack, including the algorithms, the computers, and the processors within it – if you co-designed, solving the problem from top down, from bottom up, and inside out, you could accelerate these applications, which are incredibly computing intensive, by a level that Moore's Law would only dream of. Moore's Law runs at about 10 times every 5 years, 100 times every 10 years. In the last 10 years, we've accelerated AI about a million times. A million times versus a hundred times. A million times compounded over 20 years gives us an opportunity to address some of the most incredible, most impactful challenges of humanity. That's you. And so we've been thinking about accelerated computing and this co-design idea for a very long time.

After some 30 years or so, each of these different fields of computing domains became within reach. One of the first ones was computer graphics. Somebody told me about 10 years ago that it would take 30 years for us to solve this incredibly hard problem called ray tracing for computer graphics. Literally following every photon of light as it bounces around the room, eventually reaching your eyes. Using ray tracing, you could solve for really interesting computer graphics problems and create photorealistic images like this. That was 10 years ago that it would take 30 years. It was the computer graphics problem that was always the future. And literally today, we ray trace every single pixel in a computer graphics program in our video games. Not only do we ray trace it incredibly beautifully, we do it at several hundred frames a second, at as large a resolution as you like. We've taught an AI how to, we've taught our computer how to simulate with first principle simulations for very few pixels. And then we use AI to predict the rest of it. We teach an AI what an image should look like, and it generates the image for us. It's temporally consistent. It's spatially consistent. It's incredibly beautiful. It looks even better than we compute.

Each one of these different domains is becoming within reach. About 10 years ago, we started talking about self-driving cars. Today, I think we are at the ChatGPT moment of self-driving cars. There's no question in my mind that within the next 10 years, almost every car that gets manufactured will have either robo-taxi capability, or if you like to drive yourself, you still can, but it has the ability to be a robo-taxi. That future is just around the corner. Each one of these domains is within reach.

Now, of course, we now have the ChatGPT moment. The last year we've seen incredible progress in generative AI in large language models. These ideas made it possible for us to take an AI that we thought was magical but hallucinated a great deal. It went from essentially cute and very interesting to something that is incredibly useful. This last year, and over the last couple of years, we saw breakthroughs in multimodality AIs. Not only do you understand the word 'cat' and the letters 'C-A-T', but you could look at an image and hear the sound 'meow' and recognize all of those words; all of that information is aligned to the same place in your brain. And we can now do that with all kinds of different modalities, which is very important to you. We made huge breakthroughs in reasoning capabilities, to be able to decompose through composition. Break down a problem we've never seen before into routine things, and through that composition, solve problems step-by-step, reasoning through hard problems. The ability to do multimodality reasoning and to be grounded by different sources of information is going to be a revolution even for your industry. It is clearly a revolution in ours. The idea that we would use multimodality sensors is very sensible. But the idea of a self-driving car stack that can think because it can reason through and experience a situation it's never experienced before. Reason through it step-by-step and be able to solve that problem, navigate through it. Incredible capabilities. It expanded the operating domain of self-driving cars tremendously. It's now the case that we are very certain we don't have to test every single car across every single scenario for that car to do well; just like us, we can now have a car that can think and be basically intelligent.

These techniques have made, and of course, agentic capabilities – the ability for agents to reason, use tools, work with other agents – completely revolutionary. And so these breakthroughs, in the time that I've been here, are permeating your industry, permeating life sciences – some of the most exciting work that I've seen in a very long time. And so today we announced a very important partnership. Before I get there, let me say a couple of things. We announced, of course, some of the work that we've done with all of you. We've brought an accelerated computing platform. But on top of that are a suite of libraries that we're very proud of. Parabricks for gene sequencing. MONAI, an open-source platform for medical imaging. And one of the most important ones is BioNeMo, a platform that understands geometric structures like molecules and proteins. These platforms are used by many of you in the room, and I'm very grateful for that.

Several announcements were made, and before I say that, there are so many partners here – a couple of hundred different companies – including pharmas, hospitals, or startups. There are startups in robotics, surgical robotics. There are startups in robotics labs. There are agentic AI companies here, helping with healthcare diagnostics and also some really cool work being done by AI scientists. Part of being at the JP Morgan event is that large companies meet small companies, and so many of them are doing revolutionary work. I'm so grateful that all of you have chosen the NVIDIA platform to work on. Our platforms ended up achieving some really great results. MONAI has been downloaded some six million times. We achieved the Guinness World Record for gene sequencing. That's cool. I've always wanted to be in the Guinness World Records, so that's cool. The vast majority of the world's structure prediction models are built on NVIDIA today. And so, I'm really proud of that. And on top of the BioNeMo platform are a whole bunch of pre-trained models. You use it for data processing. You use it for training these biological models. You use it for fine-tuning. But we also have a whole bunch of pre-trained models and a bunch of data that you can start with, and you could apply your data to fine-tune your molecules. Some of the models that we've created, participated in, and jointly developed are LaPorteina for protein design, ResNet for molecular synthesis, Kermit for predicting toxicity, and Evo2, a DNA foundation model. These foundation models, of course, start with us trying to learn the representation of proteins so that we can create a foundation model for protein. But the moment and time when we're going to learn a representation and create a foundation model for cells is just around the corner. The multi-domain systems and CodonFM for RNA design are making really terrific progress.

And so today we announced a large number of partners that are working with us in BioNeMo, and I'm very grateful for that. And we also announced a really landmark partnership with one of the most important companies in the world and a really great friend, Dave Ricks, and Lilly. So, I won't tell you more about it. I'm going to let the two of us describe it together. Dave has been the CEO of Lilly since 2017. And in the context of Lilly's history, it's a 150-year-old company. He's been in the company for 30 years. So he's basically a new college grad in the context of Lilly. And I'm anxious to learn from him how he learned so much in just a short period of time. But he's been with Lilly now 30 years, and as you know, he has helped guide and build Lilly into one of the most valuable companies in the world, and surely one of the most important companies in the world. And so if you could join me in welcoming my guest, David Ricks.

Thank you, Dave, for being here.

So, Dave was an Eagle Scout and went to a juvenile delinquent school. Just to be clear, I was placed there as an accident. It wasn't. It was no, that was a very good school. It was very affordable. So, in 2017, you became CEO.

Yes.

My question is this: What was Lilly like and what was its vision for the future of life sciences then, and what is it like today, and what is your vision for the future of life sciences in that context?

Well, in 2017, we were almost 140 years old – just a year older than that – and had a pretty well-established company. We had been through a difficult period of time in our industry, and we'll get into this a little bit later. We are plagued by – as many people in the room know – the cycles of innovation that are actually longer than the reward cycles, on average. So you have this peak-trough cycle; you're peaking and troughing. In the troughs, of course, you either don't survive, you end up as the back end of a hyphen on another company, or you learn how to survive and do difficult things. I think it's true that Lilly is the only major pharma company that has not merged or combined to get through such a period. We've been through a few of them. So, I think we've developed a bit of a DNA for scraping by in these tough times. And one of the things that really stuck with me – I was a leader on the executive committee at the time – was that we went through our last cycle in 2010, 2011, 2012. You have to be so relentless on invention because that time cycle is brutal. When you have a patent cliff and you have nothing to replace it, you have to rescale your whole company. And imagine doing this every 10 or 15 years; it's impossible to get momentum. People leave, you lose inherent knowledge, etc. So, we set about to do that. And I think that problem can be attacked two ways. One, you can say, 'Okay, we'll just have better ideas.' But as you may know, that's difficult to sustain. Even if you have a good idea, everyone thinks you're smart. They think about that about Lilly now. But it's hard to sustain. So, of course, we worked on that – more invention. But the more important thing we did was speed up invention. So we systematically took apart the R&amp;D process – literally every step, and there are hundreds of steps from candidate selection to first approval – and we squished the time. Still today, Lilly is probably about 40% faster than the next scaled pharma company on average across all therapeutic areas, so we can invent things inside the patent cycle.

Yeah.

Then you can start to grow.

Yeah.

So I think that was a notion in 2017 which we've actualized along the way. Then, of course, we did a lot of things to drive more invention. We were lucky enough to be early on an idea called GLP-1 in 2006. We launched the first one in the world.

Never heard of it.

Yeah, we fiddled around. Is it doing well? If it weren't for you, it would be the most important idea in the stock market. But it's a pretty good idea for mankind. We fiddled around with it for like 12 years.

Sounds like a chip, GLP-1.

Yeah, it does.

GLP-1. Is there a two coming?

There's a three coming. So there is a GLP-2 that's actually a real protein.

Is it really? Okay.

It's a protein. It sort of does the opposite. But you don't want that. What we've done is combined two hormones.

Very small market. I've got to tell you.

That's right.

Extremely small. I don't know healthcare, but I'm guessing people should sign up on GLP-2 now because tirzepatide, two proteins fused together, is a technology we've developed too. And there's a triple-acting one coming next year, in 2027. So that'll be pretty interesting. But anyway, we caught that wave. Our competitor innovated into obesity. We chased and executed, I think, quite well to become the market leader last year. So we not only now have an engine that's faster, we have a tremendous success cycle with this one idea. The challenge before us now is how do we find another success cycle before that one runs out – hopefully a lot sooner than it runs out – and get exit velocity, which really no major company in our industry has had. They've just had these cycles.

So, you said something earlier, and I have several of my employees here, and they hear me say this all the time. The fundamental purpose of the CEO is to create the conditions by which – our job isn't to create ideas. Our job is to create the conditions by which great ideas can systematically arise. What you just described is essentially Lilly with wisdom – that you have to create the conditions by which these great inventions can happen. One of the things – we've spoken before about the early days of NVIDIA getting into AI – and I would say that without exception, probably the single most important thing that we did was investing in the infrastructure, creating the conditions by which amazing AI researchers can come to our company and great inventions could arise. Today, we're quite silent about this, but people are increasingly discovering that over the course of the last 10 years, one of the best decisions that I made in the beginning was, at the time, we couldn't afford it. But nonetheless, I built one of the largest supercomputers in the world for NVIDIA to use. At the time, I had nobody to use it because NVIDIA had very few AI researchers. But the problem is, if you don't have AI researchers and therefore you don't have the instrument, you'll never have the AI researchers because scientists need the instrument necessary for their science. If you want to attract the world's greatest particle physicists, if you don't have a particle collider, you're going to have a very hard time doing that work. And so I came to the conclusion that the right answer is to create the conditions for great AI work to be done. I built that supercomputer, and we attracted some amazing people. Today, we do frontier work in physical AI, biological AI, and robotics AI. The work that we did in self-driving cars is revolutionary, which led our conversation to the idea that AI is starting to make enough progress that we might be able to apply it to tackle some of the most extraordinary challenges of humanity, which is biology.

Yes.

And the two of us thought it'd be amazing if we had the largest computer company in the world and computer science company in the world partner with the world's largest life science company. And it's as if we created this lab where we are essentially one company, combining all of the best amazing things together, which led us to our announcement today.

Yeah.

And so exciting.

Today we announced it.

And as you know, there are like four parts to this. We bought a bunch of chips, and we're building – I think it'll be finished this week actually – the largest dedicated on-prem biology supercomputer in the world. That'll be in Indianapolis, which is the world center for biologic discovery, by the way.

I was going to say earlier, because of the selection of Lilly's headquarters, it is exactly the reason why it has never merged with anyone.

Maybe so, that could be true. That could be true. There are a lot of artifacts with that.

Yeah. I think that seriously, there's something to like if you manage to make it all the way.

Yeah.

If you manage to make it all the way, and you're a discovery chemist or biologist, you really aren't going to leave, right? I mean, you made it all that way. You're going to stay. So, we have great retention. Anyway, we're building this huge system, so we have massive compute. Dave's invited me to visit him many times. He's never.

Actually, you did come in 2018. I don't know if you remember that.

Yes, I did.

Yeah.

Actually, just as a sidebar, that was the first time we met, and you gave a talk to our management team – a room about this size – about AI in 2018.

Yeah.

And I guess I was lucky enough to be in the 100% of the audience I could see. I could see it in their eyes: 'Nonsense.'

Honestly, it blew my mind. What you said blew my mind to the point where I spent several months reading about some of these things, which sounded like science fiction.

Yeah.

And now it's fact.

Yeah.

It's incredible what you built, and it's great to partner with NVIDIA on this. So, with the supercomputer, we're going to put together a research team here in the Bay Area. So if there are any smart scientists or computer scientists who want to work at the center, it'll be a joint Lilly-NVIDIA AI lab. We're going to develop new data because, as anyone who knows about this problem understands, you can train models, but if the data is an inch thin, you don't get very far, and biology is largely unknown. So we need to create massive experimentation for the purpose of training machines, and then we need to build on the work that NVIDIA has done with the models you've created to ladder up to even more sophisticated predictions.

That's right. So, super exciting! And so, one of the important things to understand about AI is that it's easy to think about it as a multi-layer cake. At the lowest level, you need some energy for these computers, and then of course, you have the chips and the computers. You have the infrastructure layer. That infrastructure layer is about how you cause this computer – it's kind of like the operating system of AI. How do you cause this computer to learn, process the data, learn? How do you guardrail it? How do you fine-tune it? How do you teach it? And so that layer is kind of like the HR department of AI.

Only they tell better jokes.

Exactly. And so that's the infrastructure layer. The layer above that is the models.

Yeah.

And the layer above that are the domain-specific data and flywheel. And one of the areas that's really exciting is the idea that we would be able to train models, synthesize proteins or chemicals, go put it into a robotics lab, collect more data, and then take that data back into our model. This flywheel of data generation – or model protein generation – using AI, collecting ground truth experimentation, and then putting that scientific flywheel on steroids. That future is just incredibly exciting. So, we're systematically bringing together some of the brightest minds in the field, in the domain expertise of drug discovery, and some of the brightest minds in computer science. Together, between the two of us in our co-innovation lab, we'll have essentially every layer of that cake and put together, hopefully, a blueprint for what is possible in the future of drug discovery.

I was going to tell you this. I was going to tell you earlier. I was going to tell you the story from 40 years ago. So, I guess 43 years ago, I was the first generation of engineers where the concept of computer-aided design was invented. Before my generation, my managers, that generation of engineers, would design a chip, and it would be a hit, but they would go several years without another hit. Then they would design another chip, and it would be a hit, and then they would go several years. It works now.

Exactly.

Exactly.

And our generation came along, and we were able to represent the transistor, the logical gates, the functionality. We learned the representation and described it in software. We did that 43 years ago. Finally, a computer could represent your domain and accurately simulate it. It's right to do as much in situ, in silico, as possible. And so today we design massive chips. 15,000 people come together to design a computer system. And we just taped out Ver Rubin. Billions of dollars of R&amp;D goes into it. The computer when it's done is three tons – a million and a half parts. And six brand new chips, 220 trillion transistors. I mean, it's gigantic systems. 15,000 people coming together, and that computer is going to work the first time. It does exactly what we expected, and every single generation we build upon the last generation. Every single generation we build upon the last generation. I think your time has come for that.

Yeah.

Finally the computer – a million times, a million times, a quadrillion times of computing power later. I think finally we might be able to represent one of the hardest problems in the world, which is human biology. And I'm really hoping that your industry moves from drug discovery, which is kind of like wandering around the forest looking for truffles. Literally, as a sidebar, we used to have a department of soil discovery. Seriously, we would send people into tropical forests and scoop up soils and bring them back to Indianapolis.

Uh-huh.

And refine out what became antibiotics. In fact, the most important antibiotic in the world is still vancomycin, the last resort antibiotic in the hospital. We couldn't run hospitals without it. It was discovered in Borneo in a soil sample by Lilly.

Now, how did they know to go there?

They would just go to exact locations because fungi produce tools to fight bacteria, so they'd dig in the soil and discover these naturally occurring defense mechanisms, refining them into drugs.

Huh.

But that is true drug discovery. Okay, when you think about it, right? That's like you could get malaria doing that job! That was, and that was in the '50s. That was 70 years ago.

Well, see, now your job gets to be just like my job. You never have to leave your office.

There we go. Do it all in silico.

Yeah. So, I think that's what really excites me. The concept that we could have computer-aided drug design.

Yeah.

And this is going to be, of course, incredible science behind it. It's incredibly complex. Human biology is incredibly complex, and it's still going to be a decade yet. But I really think that this announcement between us could be a blueprint.

The start of something. I hope you're right. I mean, we need it, right? I think if we think of all the unmet needs left at a conference at JP Morgan, you're reminded of the incredible pipeline of the industry, but most of that is sort of chipped out of stone – it's hard work. And especially, occasionally we can harness systems, like when monoclonal antibodies came around, we basically hijacked biology's way of making solutions to infections and other things. But mostly, what we do is really empirical, chipping away and very difficult. Each small molecule discovery is like a work of art. There's only one of them, and one brush stroke, and it's wrong. If we can make that an engineering problem, versus this sort of discovery, artisanal drug-making problem, think of the impact on human life.

The first chips that I worked on, my first generation of computers, were quite empirical. There are some rules that we used, and we apply some intuition. We have no clue how it's going to perform. We know that it's going to perform better than the last one we built because we made mistakes, so we could at least correct those mistakes, and we'll have more transistors and more of everything. So it's going to do better.

Yeah.

However, the functionality of it is unknown. Its full functionality is unknown. Its performance is completely estimated. Today we know the functionality of the systems we created down to every single bit. The performance we can measure. We simulate everything.

Yeah.

And so we know exactly what we're going to produce. I really believe that that could revolutionize the future. It would make that come true even for a part of human biology.

Yeah, that's right.

And so, tell me, GLP-1 – you were saying that it's really in its third phase.

Already.

And where does it go from here? What happens? What other things can you use it for? How could it change everything?

Well, I think as it turns out, obesity is a key lynchpin driver of chronic disease in adults. Like a lot of things in evolution, most of today's ailments were concerns in our evolutionary past, but we evolve much slower than our environment, so we're maladapted to the modern world. And obesity is one of those things. We grew up in a world of scarcity. Sounds like you grew up in a world of scarcity, but most people here didn't. Our ancestors did. And so, that's behind me. There was no need for an off switch on hunger.

The word is abundance now.

Abundance. Yes.

And we live in a world of abundance: abundance of intelligence, abundance of productivity, abundance of those kinds of things. And I don't know what you were thinking about, but my life is surrounded by abundance.

But unfortunately, we're all in caloric abundance now. And there was no need for us to wire in an off switch, evolutionarily. So, that's why we have obesity. And that leads to many chronic diseases that ail people and probably shorten life. So, I think by having a pretty effective set of tools – going to get more effective, and I'll get back to that in a second – to really help people manage that, to create an off switch synthetically in a way.

Yeah.

We can downregulate a lot of diseases, over 200 chronic diseases.

No kidding.

So, the two big evolutions that are going to happen in the next 24 months are real progress on more choices. So, GLP-1 is one peptide, but it's in a family. And by combining two in tirzepatide – GIP plus GLP – we see we can get better performance and better tolerability. I think you expect more of that kind of thing in the future. So within this super family of proteins, we can harness their combined strengths to really have much more tolerable drugs that are even more effective – effective in the maintenance phase, effective in inducing weight loss, and for different patient characteristics. That's coming. As I said, just reducing weight loss has so many downstream benefits. And that's the second thing, which is use cases. So, we know you lose weight. If you take our Zepbound today, you'll lose 23% of your body weight on average. But what we're starting to uncover is a series of obvious things like reduced heart attack and other metabolic systems that improve diabetes. Pre-diabetes conversion to diabetes drops by 93%. Imagine if we treated the country, where we have 70 million people with pre-diabetes, with Zepbound, we would literally have 93% less diabetes in our country. That's a profound finding, and hopefully with the government access deal we signed with the Trump administration, we'll be able to do something like that. But there are many now non-obvious, I think, use cases, or less obvious ones, inflammation being a primary one. So, being obese causes excess inflammation – not acutely like in response to an event, but chronically – and that's not good for you. It's not good for your cardiovascular system. It's not good for your joints. And so spontaneously in our early trials, people would report, 'Gosh, I've lost weight, but actually I can stand up from a sitting position for the first time in 10 years.' My knees don't ache as much. My back feels better. Or some people with Crohn's and colitis reported a kind of resolution of their symptoms. So why is this happening? It's because we're sort of taking down that chronic inflammation at a system level. So we're doing a bunch of studies. The first one read out last month on top of a medicine for psoriatic arthritis – a kind of arthritis – and it boosted the effect of that medicine by about 50% to co-prescribe Zepbound with it. So we're going to take that on medically, because that's how the medical system adopts innovations; they need the use cases. Perhaps similar to adopting AI technology, you need to prove the value in a particular setting. We're also starting a number of brain health studies right now, and we have a special-purposed GLP-1 GIP for brain conditions, particularly addiction, which is really a major modern problem. It turns out that for similar reasons – that these medicines downregulate your appetite, which is not really driven by our need for more calories but driven by other self-learned behavior loops – it can do the same thing or a similar thing for other harmful self-learned behavior loops like gambling, alcohol consumption, and smoking cessation. So, we're exploring all of these as well, which include – I hope it doesn't affect working too hard.

No, it's only the adverse ones we're trying to edit out.

Yeah, it's only the adverse ones. But it's a common pattern with over food consumption. Actually, there's a parallel for that. That's just a comment for all the startup CEOs. We've got a lot of startup CEOs in the room here. Be careful if you find your willpower is starting to diminish. Stop microdosing.

Yeah.

So, anyway, that's very exciting.

That's so interesting.

Yeah.

And then, I think on the horizon, people are working on much longer-acting versions, so you can take these less frequently. Of course, we'll launch our oral GLP-1 this spring, which I think is a major breakthrough, not just for convenience, but for global reach. It looks simple – our medicine in an autoinjector – but it's actually one of the most complicated drugs marketed in the world from a manufacturing perspective. And we have to do it hundreds of millions of times based on the current demand. We just launched in China, India, and Southeast Asia. There's a lot of obesity there. We cannot possibly meet all that demand with just injectable systems. So we need to get to Southeast Asia, where serious diabetes is a huge problem.

Huge problem.

Yeah.

And Southeast Asians sort of lost the genetic lottery of obesity because at much lower body weights, small increases in the amount of obesity trigger more diseases. So they need to use something to mitigate obesity. Hopefully diet and exercise. If not, they can use our medication, but we have to make enough. And having an oral form that's chemistry – it's not relying on protein synthesis and then putting it in these sterile injectable systems – just an oral pill. We can scale that massively. So that will launch this year as well. So, this one idea, you're going to ride this for another 50 years, right?

Right. We're hoping to. We're learning from you.

My gosh. That's... Hang on a second. I'm convinced. I'm convinced. GLP-1. It's the second best technology.

That's right. Exactly. Ours is not un... Blackwell. Blackwell is number one. GLP-2. GLP-1 number two.

Ours is not universal to the entire economy, just to the human economy.

Yeah.

That's incredible.

Very exciting. And one challenge we have is how can we keep inventing things that are better and better, enough that people will pay for them, to improve beyond the patent cycle.

But has there ever been a drug? Has there ever been a life sciences technology that has benefited humanity so broadly?

The only other class of drugs I'd say that did something like this, I alluded to earlier, is antibiotics. The discovery of penicillin invented modern medicine. If we subtracted antibiotics from our lives, we couldn't have modern dentistry.

Yeah.

We couldn't have surgeries. We couldn't do it. So now we take that all for granted. But when Fleming self-dosed this weird mold he grew in his lab, that was the start of a major wave. And that lasted into the '90s. So that was a 60-year cycle with 100-plus new medicines. I think this could be like that.

Yeah.

Which would be profound, but this is not for an acute infection. It's for chronic disease of the modern world. That's what we're affecting.

Well, Dave, did you ever realize that you were going to have such an easy job?

My wife asked me that a few times. Like, 'Why aren't you working?' One incredible discovery, one incredible thing. You were just running around the forest, and you discovered this thing called GLP-1.

Yeah, that's what I've imagined. You're digging up stuff and you found this incredible truffle, and it's solid for 60 years.

Yeah.

Yeah.

Actually, what's the history of this? So, it goes back to the '70s, and German scientists discovered this thing called the incretin effect. We call these GLP-1s part of this incretin family. These are hormones excreted by our gut which signal the rest of the body that you're fed, and we overboost those – and that's what is happening. But he observed that if you give sugar orally versus intravenously, you get a very different insulin response. Insulin is like the opposite. It stimulates absorption of sugar. It was slower if you give it orally. And so that's what's called the incretin effect, which was the first insight that somehow your body is doing something different when the gut is involved and when it's not. And that then led in the '80s to the discovery of GIP first, then GLP. Those are the two parts of Zepbound, and later, a whole another set of hormones. But one of the things I hope we can crack with our supercomputer and our team is that here we had targets, but it was really difficult to drug. The half-life of the native human form of GLP is like seven minutes. So to give that as a medicine – the native peptide sequence, which was identified in the '90s – you'd have to walk around with an infusion all day and all night. So that doesn't make for a product. It wasn't until we figured out how to extend that life first to twice a day, then to once a week, and now people are working on monthly and even beyond that, that we could make that an effective product. So one thing in AI drug discovery that is really working is this ability to create massive combination possibilities and then test those in silico and filter out good ideas. We're doing that at scale now. We can do that at even bigger scale with our collaboration. The other side is discovering. So that's the key to discovering the lock. Can we find more biology targets using AI? That is really the holy grail, because if we put those two things together, then we can model the whole system at once. Could be super exciting.

Yeah.

One of the things that Dave really wanted to do was to put the AI lab, the co-innovation lab, here in Silicon Valley, and even close by in AI city. San Francisco is really the epicenter of a lot of AI researchers, and we have an office here. So this is going to be either in South San Francisco, which is really the biotech hub of the Bay Area, or we can do it up here.

That's right. We want to go where people want to live.

Yeah.

Well, San Francisco is pretty cool.

It's cool.

Yeah, it's cool as well.

Yeah.

Yeah.

I've heard from just one other person.

We're very adaptive. We used to be good at basketball, but now we're good at football.

Uh-huh.

And so, we used to be good at chemistry, but now we can be good at AI.

Well, you're just good at suffering.

Yeah, we're good at something. That's true. Better than the alternative.

Yeah.

Yeah.

It's incredible.

And so, GLP-1 beyond – one of the things that a fair amount of Silicon Valley is talking about is longevity and aging.

The absence of...

Subtracting aging. And so, tell me, what is the technology behind that? Is it?

Well, it's an interesting topic. Obviously, it's attractive to a lot of people, because who wants to get old? Sometimes I just want it to be over. There are a number of... Yeah, I get that too. There's a lot of biology on why individual cells expire, and you can extrapolate that to cell systems, then organs, and then potentially the whole organism. But as we were talking offstage, that is not really a problem we work on that way. So that idea is essentially, can we extend the maximum shelf life of a human to something beyond what it is under perfect conditions? So let's just say under perfect conditions we can live up to a hundred years, and then for maybe good reasons, the system shuts down, right? I think it would be a weird world if people lived forever. Why would we reproduce? How do we evolve? There are a lot of problems with that kind of thing, even philosophically. How does nature fix that original design? Yeah, philosophically though, we would have a very weird world, I think. But I understand why people pursue it. We're more focused on a more practical problem, which is: if the maximum shelf life is 100 years, how do we get more people a better shot to get that full life? And the way we do that is by knocking out disease. So the reason people perished, if you look at life expectancy in our country in 1900, it was like 46 years old for a male, and the biggest factor there was child death. So you lost life because you died when you were young at a pretty high rate, mostly from infection. By having antibiotics and vaccination and other tools to manage childhood disease, that quickly shot up. From 1960 until now, we've added about 10 years of life expectancy, mostly through chronic disease extension. Cancer care has improved dramatically. Most companies in this room have had a big role in those chronic disease management, HIV/AIDS, and other new pathogens have been conquered. And that's, now we're up to almost 80 years in our country. Actually, the number would be more like 84 if it weren't for opioids and traffic deaths, which are exceptionally high in the United States – both of those.

So, self-driving cars can help with one of those.

Maybe GLP-1s will help with the other, because we're studying opioid addiction as a solution there.

But we chip away at it this way. And of course, as people live longer, the incidence of new maladies of aging rises. So the next frontier for us beyond GLP, that I'm really excited about and interested in, is dementia and diseases of the aging brain. Because as the rest of our bodies are able to carry us into our '80s and '90s, this is something we haven't really figured out how to address. For quality of life, but also quantity of life, that's going to be an important frontier. We're spending a lot of effort in that area. We've got some exciting programs running now in studies, but I think through drug discovery – simulating brain tissue and how to look for new targets and the interaction between targets we don't understand (there's inflammation plus protein misfolding happening in the aging brain) – perhaps we can discover something really exciting and new. If you take a step back and look at our co-innovation lab, the first thing we have to do is set up the computing platform for the researchers to do the work. And so we have the computers, we have the infrastructure layer, and we have BioNeMo, and we have a whole bunch of models – models and model architectures we've already invented. We'll get our scientists together, and they can start collaborating in that particular area, just building the foundations. But if you had a wish list for the researchers – I know that, and certainly it is the case with me. I try to influence the researchers' direction, but I try not to be directive.

Yeah.

And obviously, the reason for that is because we don't know what we don't know, and we don't know what can be discovered. There are many things that are discovered that, quite frankly, we didn't even know were possible. But once it's created, our innovation brain can kick in, and together, we can try to figure out how to bring that to the market. But if you had a direction that you would like to set them on, in what direction would you hope that they do some research?

Yeah, I think there are like two basic problems, and I think within these we'd have to narrow the scope to make progress and feel achievement. The first one, there's a lot of momentum in our space already, which is what I talked about: the drug design, engineered drug design. You could argue a lot of drugs these days fall into that category. You know the target because it's been around and well-profiled, and you're better customizing the key to the lock. But there are new modalities that have emerged – RNA, gene therapies, etc. – that really haven't been optimized because they haven't been around as long. So I think that whole suite of problems around drug engineering, drug optimization, is pretty tractable, and I think the NVIDIA scientists, coupled with ours, could make a lot of progress pretty quickly there. That solution, by the way, would be highly amenable to our Tune Lab kind of interface we've built.

Yeah.

For all of our biotech partners as well. Better drug making through in silico, engineered design. And just so you guys know, for anyone who doesn't know about Tune Lab, this is a platform where Lilly and startups or third parties could work together, both contributing data.

Yeah.

To advance a particular space, and it's built on top of a platform that is called federated learning. It's called NVFlare, that we contributed to, so that developers and researchers don't have to aggregate all of your data, co-mingle your data, but you could still train a model together so that you can benefit together. The thing that's been really exciting since our announcement – all day long, the number of startups have been really excited about Tune Labs and co-innovation and how they could be involved, just coming out of the woodwork. So I think the vision you have for Tune Labs and the work that you did in building up Tune Labs is completely visionary, and it makes possible collaboration for AI researchers that are not in the same company. It's very hard to data, protecting intellectual property, but the process of improving their idea improves the training of the model itself. So we all gain by participation. There are no fees. We do curate it. So there are legitimate biotech projects, but we will add the product of our work together to the Tune Lab interface. And so not just Lilly scientists can benefit, but many biotech scientists. The other side of the equation, of course, is the target. Here, I think we need our robotics effort to really kick in. Why do we have more targets, and why do we understand the targets we have better, which are probably structurally more complicated than we understand? That's one of the reasons drug development fails: we think we have the target, but we don't really understand it. That's because we need massively more amounts of experimental data on specific, good targets. So I think here we'll work with you on flushing out. We already have one robotic lab running wet lab, but we'll build more. We can have them running 24/7, experimenting around a target space to really fully profile that, and then couple that with those engineered drug designs. So that's a little bit harder problem. It's more empirical, but I think machines are made to work day and night to solve this problem. And that flywheel is going to fly. I think, Dave, if you look at some of the advances that we've had in other domains, the first thing is you need the flywheel to eventually land at ground truth. So, you have to have physical world experimentation, collect that data. And you close the loop that way. Eventually that model becomes sufficiently good, that foundation model becomes sufficiently good, and you could teach it how to generate – to be generative. Eventually, there's a model that is being tested against another model, and this other model is the world model or the target model. The target model, along with the model that you're training, runs in a closed loop, so essentially, the lab is another model.

Yeah.

And so you eventually have to ground it again by producing and synthesizing the proteins and collecting real data. But we get ourselves in a synthetic data flywheel, and that synthetic data flywheel is incredibly effective. I don't think that's been attempted in our industry at scale, and I think we'll do that here. But I think really, taking a handful of targets which we highly suspect will be useful in key diseases, and really doing the full profiling of those in robotic wet labs to train the data set, and then use the machines to fill in the space and make better drugs, because we understand this is so exciting. It's singularly true that finally we're going to have a lab where the expertise and the scale of that lab is going to be sufficient to attract people who really want to do their life's work in that intersection.

Yeah, we'll be so excited.

So I'm super excited about that. And so one of the things that is really cool about this conference is large companies and small companies getting together. This year, AI scientists – there's a company I met today. We've been working with them for some time. I hope they don't mind that I mentioned their name. Eddison is really terrific.

A foundation model company is going to build both the life sciences lab and the AI lab, or the factory—a real robotics factory—and a large-scale system. LILA and other companies are incredible; they're probably in the audience.

What are some of the companies that you've seen? Robotics labs, AI scientist companies. Of course, Agentic Healthcare AI assistance, the work that Abridge and Open Evidence are doing, is really cool. What are some of the areas that you've seen that are really cool?

I think for AI, the most tractable problem now that you're seeing more and more is healthcare service. This is not as complicated as what we're talking about here today, but rather, how do you replace human-level service with agentic service, AI service? It seems so obvious for what is the least productive part of the entire economy to adopt AI. But there are a lot of frictions for that. A lot of our discussions are, &quot;How can we collaborate?&quot; We run what I think is probably the largest direct pharmacy platform in the country, Lily Direct. It's only a year old, but it's annualizing close to a billion dollars a quarter right now—four billion a year just selling pharmacy. People want to say, &quot;Can Lily work with us to use your market weight to force adoption and work against insurance companies?&quot; Let's be honest, they're not into change. Physician groups are frightened by some of these technologies. But we really do need to make the US healthcare system more efficient. In doing so, we can actually have more room for innovation, more room for adoption of cutting-edge medicines, and maybe more accurate and comprehensive workup of people.

That seems inevitable, but what can we do to speed that up and really harness that? There are a lot of new modalities, as I was mentioning earlier, to drug targets. In the last 10 years, without AI, the industry's productivity on new modalities is accelerating, and that's exciting. Yet it's early days, so a lot of companies are combining new and old modalities into bifunctional medicines—that's a hot field where you have a targeting part and then a warhead part, say, to kill cancer cells. Even just refining how we get these medicines to the right tissue is an important problem, and there are a lot of interesting new, different approaches happening that I took meetings on today that were pretty interesting to me. That's the drug-making side, and I think AI can help us accelerate that, but a lot of smart people are working on those problems. Of course, a lot of people want to talk about GLP1s—that's my life.

It was good you said small companies and big companies getting together. Here, we're the small company and you're the big company.

Cut it out.

And we're getting together.

Cut it out, cut it out.

Lily probably had a reputation 10 years ago when I started, around 2017, as a little bit of a sleepy Midwestern company. But here's a fun fact for the computer people: the first approved biotech product made by a living organism, a medicine made in the most modern way, was a Lily product, Humulin, which we collaborated with Genentech on. Then, 12 years later, we bought the first supercomputer in the pharmaceutical industry and put it in Indianapolis. It was a Cray supercomputer called Big Red.

Our company logo is red.

Big Red. Very clever. We designed the first approved medicine designed on a computer on that thing. It's called insulin lispro, which is Humalog. It's still used by Type 1 and Type 2 diabetics globally today by playing around with amino acid sequences empirically.

Always trying to convince me that Lily is cool.

We are cool. We are cool. We've been working with computers and the cutting edge of science and computer technology.

You had me at hello. At hello. This just makes tons of sense because it's a natural evolution of our company. So awesome.

It is so awesome to work with you and your team, and I am so excited about the work that we're about to do together. I can't imagine a more worthy, more complex, more exciting field to apply computer science to. For someone who's dedicated a whole career in basically one job of building computers, the opportunity to work with you and Lily and the scientists there in service of the next breakthrough can't be more exciting. I want to thank you for your partnership and for personally driving this. The two of us teaming up together, pulling together the might of our two companies, hopefully we can bend the arc of history and see if we can make a difference. That's super exciting.

That's so exciting to hear you say that. Thank you for helping make this come together. We're just getting started, but this could be a new day. If we can accelerate progress, even if we set modest goals, I think we can accelerate progress in a use case for computer technology that has to be the most personal and impactful for our country and for the world, and for an industry that really needs to find more ways to be more productive with R&amp;D dollars. It's a worthy try, but we're going to do more.

We're going to make it happen. We're going to make it happen. Ladies and gentlemen, David Ricks and the second most—I'm just kidding. Thank you. Thanks. Thank you. Great. Thank you. Thank you. Fun. That was fun to do. Thank you. Cheers.
                    </div>
                </div>
                
            </article>
            
        </main>

        <footer>
            Generated by Follower Tool
        </footer>
    </div>
    <script>
        function toggleSummary(id) {
            const preview = document.getElementById('preview-' + id);
            const full = document.getElementById('full-' + id);
            const btn = document.getElementById('sum-btn-' + id);

            if (full.classList.contains('expanded')) {
                full.classList.remove('expanded');
                preview.style.display = 'block';
                btn.classList.remove('expanded');
                btn.innerHTML = 'Read more <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>';
            } else {
                full.classList.add('expanded');
                preview.style.display = 'none';
                btn.classList.add('expanded');
                btn.innerHTML = 'Show less <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"/></svg>';
            }
        }

        function toggleTranscript(id) {
            const content = document.getElementById('transcript-' + id);
            const btn = document.getElementById('trans-btn-' + id);

            if (content.classList.contains('expanded')) {
                content.classList.remove('expanded');
                btn.textContent = 'View transcript';
            } else {
                content.classList.add('expanded');
                btn.textContent = 'Hide transcript';
            }
        }
        </script>
</body>
</html>